REG - Hikma Pharmaceutical - Results of EGM

Hikma PharmaceuticalsAnnouncement

20/05/2022 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220520:nRST3042Ma&default-theme=true

RNS Number : 3042M  Hikma Pharmaceuticals Plc  20 May 2022

 

Hikma Pharmaceuticals PLC

Results of 2022 Extraordinary General Meeting

LONDON, 20 May 2022  Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK)
(OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Extraordinary General
Meeting ("EGM"), held at 1 New Burlington Place, W1S 2HR, London on 20 May
2022 commenced at 10:00 am. The Proposed Special Resolution was passed.

Copies of the special resolution passed at the EGM have been submitted to the
FCA's Electronic Submission System and will be available from the National
Storage Mechanism.

The total number of votes cast on the poll for the resolution (the full text
of the resolution is detailed in the notice of the EGM dated 25 April 2022) is
set out below. The number of Ordinary Shares in issue as at

20 May 2022 was 238,253,038.  There were 12,833,233 Ordinary Shares held in
treasury, which are not counted in the voting capital of the Company which,
therefore, was 225,419,805.

 Resolution                                                                  Votes For    %      Votes Against  %     Total Cast   Withheld
 1. Approve the Conversion of the Merger Reserve to a Distributable Reserve  165,124,425  99.99  2,080          0.01  165,126,505  2,249

 

- ENDS -

Enquiries:

 

 Hikma Pharmaceuticals PLC
 Peter Speirs                                 +44 20 7399 2670

 Company Secretary

 Susan Ringdal                                +44 20 7399 2670

 EVP, Strategic Planning and Global Affairs

 

 

 

 

About Hikma

Hikma helps put better health within reach every day for millions of people in
more than 50 countries around the world. For more than 40 years, we've been
creating high-quality medicines and making them accessible to the people who
need them. Headquartered in the UK, we are a global company with a local
presence across the United States (US), the Middle East and North Africa
(MENA) and Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform people's lives.
We're committed to our customers, and the people they care for, and by
thinking creatively and acting practically, we provide them with a broad range
of branded and non-branded generic medicines. Together, our 8,600 colleagues
are helping to shape a healthier world that enriches all our communities. We
are a leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the world. For
more information, please visit: www.hikma.com
(https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2531421-1%26h%3D3823969217%26u%3Dhttp%253A%252F%252Fwww.hikma.com%252F%26a%3Dwww.hikma.com&data=02%7C01%7Cmellisa%40hikma.uk.com%7C997d2fa3727b41845d4308d7ecef5a5f%7C178c1a723d3c40afbaa754615303bcdc%7C0%7C0%7C637238385059390461&sdata=JoY1dcOqWcUS12nfDFqq49wlYgBsw3%2BZFmrlDQ4QNI0%3D&reserved=0)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMFBLFLLELEBBQ